<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Epilepsia</journal-id><journal-id journal-id-type="iso-abbrev">Epilepsia</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Epilepsia</journal-title></journal-title-group><issn pub-type="ppub">0013-9580</issn><issn pub-type="epub">1528-1167</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4963464</article-id><article-id pub-id-type="pmcid-ver">PMC4963464.1</article-id><article-id pub-id-type="pmcaid">4963464</article-id><article-id pub-id-type="pmcaiid">4963464</article-id><article-id pub-id-type="manuscript-id">NIHMS536148</article-id><article-id pub-id-type="pmid">24313671</article-id><article-id pub-id-type="doi">10.1111/epi.12480</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS536148</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA536148</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Stereoselective Anticonvulsant and Pharmacokinetic Analysis of Valnoctamide, a CNS-Active Derivative of Valproic Acid with Low Teratogenic Potential</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Shekh-Ahmad</surname><given-names initials="T">Tawfeeq</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hen</surname><given-names initials="N">Naama</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yagen</surname><given-names initials="B">Boris</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McDonough</surname><given-names initials="JH">John H.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Finnell</surname><given-names initials="RH">Richard H.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wlodarczyk</surname><given-names initials="BJ">Bogdan J.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bialer</surname><given-names initials="M">Meir</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel</aff><aff id="A2"><label>2</label>David R. Bloom Center for Pharmacy, The Hebrew University of Jerusalem, Israel</aff><aff id="A3"><label>3</label>Pharmacology Branch, Research Division, US Army Medical Research Institute of Chemical Defense, Maryland, USA</aff><aff id="A4"><label>4</label>Department of Nutritional Sciences, Dell Pediatric Research Institute, The University of Texas at Austin, Austin, Texas, USA</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Professor Meir Bialer, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, Jerusalem 91120, Israel, Tel: 972-2-6758610, Fax: 972-2-6757246, <email>bialer@md.huji.ac.il</email></corresp><fn id="FN3" fn-type="conflict"><p id="P50"><bold>Disclosure/Conflict of Interest</bold></p><p id="P51">None of the other authors has any conflict of interest to disclose.</p></fn></author-notes><pub-date pub-type="epub"><day>06</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2014</year></pub-date><volume>55</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">273278</issue-id><fpage>353</fpage><lpage>361</lpage><pub-history><event event-type="nihms-submitted"><date><day>22</day><month>07</month><year>2016</year></date></event><event event-type="pmc-release"><date><day>28</day><month>07</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>28</day><month>07</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-05 14:06:38.133"><day>05</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms536148.pdf"/><abstract><title>Summary</title><sec id="S1"><title>Objective</title><p id="P1">Valnoctamide (VCD), a CNS-active chiral constitutional isomer of valpromide the corresponding amide of valproic acid (VPA), is currently undergoing phase IIb clinical trial in acute mania. VCD exhibits stereoselective pharmacokinetics (PK) in animals and humans. The current study comparatively evaluated the pharmacodynamics (PD; anticonvulsant activity and teratogenicity) and PK of VCD four individual stereoisomers.</p></sec><sec id="S2"><title>Methods</title><p id="P2">The anticonvulsant activity of VCD individual stereoisomers was evaluated in several rodent anticonvulsant models including: maximal electroshock, 6Hz psychomotor, subcutaneous metrazol and the pilocarpine- and soman-induced status epilepticus (SE). The PK-PD (anticonvulsant activity) relationship of VCD stereoisomers was evaluated following ip administration (70mg/kg) to rats. Induction of neural tube defects (NTDs) by VCD stereoisomers was evaluated in a mouse strain highly-susceptible to teratogen-induced neural tube defects.</p></sec><sec id="S3"><title>Results</title><p id="P3">VCD had a stereoselective PK with (2S,3S)-VCD exhibiting the lowest clearance and consequently, a twice-higher plasma exposure than all other stereoisomers. Nerveless, there was less stereoselectivity in VCD anticonvulsant activity and each stereoisomer had similar ED<sub>50</sub> values in most models. VCD stereoisomers (258 or 389 mg/kg) did not cause NTD. These doses are 3&#8211;12 times higher than VCD anticonvulsant-ED<sub>50</sub> values.</p></sec><sec id="S4"><title>Significance</title><p id="P4">VCD displayed stereoselective PK that did not lead to significant stereoselective activity in various anticonvulsant rodent models. If VCD exerted its broad-spectrum anticonvulsant activity using a single mechanism of action (MOA) it is likely that it would exhibit a stereoselective PD. The fact that there was no significant difference between racemic-VCD and its individual stereoisomers, suggests that VCD's anticonvulsant activity is due to multiple MOA.</p></sec></abstract><kwd-group><kwd>New Antiepileptic drugs (AEDs)</kwd><kwd>CNS drugs</kwd><kwd>Strereoselective Pharmacokinetic (PK) and pharmacodynamics (PD) analysis</kwd><kwd>Chiral switch</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>